EDHF (endothelium-derived hyperpolarizing factor) is an unidentified mediator released from vascular endothelial cells in response to acetylcholine and bradykinin which is distinct from the NOS- (nitric oxide) and COX-derived (prostacyclin) vasodilators.[1],[2]Cytochrome P450 (CYP450) metabolism of polyunsaturated fatty acids produces epoxides such as (±)14(15)-EET which are prime candidates for the actual active mediator.[3] However, the CYP450 metabolites of eicosapentaenoic acid and docosahexaenoic acid have been little studied relative to arachidonate epoxygenase metabolites. (±)16(17)-EpDPA is the DHA homolog of (±)14(15)-EpETrE, derived via epoxidation of the 16,17-double bond of DHA. The EDHF activity of (±)16(17)-EpDPA has not yet been determined. The epoxygenase metabolites of DHA have also been detected in a mouse inflammation model.[4]

155073-46-4

C22H32O3

344.49

(±)16,17 EDP;(±)16,17-EpDPE;(±)16,17-epoxy Docosapentaenoic Acid;(±)16(17)-EpDPA;(±)16,17-epoxy DPA;(±)16(17)-EpDPA

DMSO:50 mg/mL
DMF:50 mg/mL
PBS (pH 7.2):1 mg/mL
Ethanol:50 mg/mL
Powder: -20°C for 3 years
In solvent: -80°C for 2 years